柬埔寨医疗器械注册六步流程全景
Updated: 2026-11-09 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Medical device registration in Cambodia can be broken down into six steps; the first three determine “whether the dossier can be submitted”, and the last three determine “how long it takes to obtain the certificate”:
- Classification — determine the A/B/C/D class under AMDD Annex 2 (non-IVD) or Annex 3 (IVD); for multi-purpose devices, take the most critical intended use under Article 4(4);
- Opening a CamPORS account — the local company registers online and submits credentials; originals are verified by a DDF official before access is granted;
- Dossier preparation — administrative documents (application form, LoA, DoC, ISO/GMP certificates, company documents, labelling) are prepared as paper originals, while technical documentation is compiled to CSDT as an electronic copy on a USB drive;
- Hybrid submission — online data entry + paper originals + USB technical dossier, delivered to DDF in parallel;
- Fee payment — DDF notifies the applicant to pay once its assessment is complete; after payment, the application enters committee review;
- Final committee approval and certificate issuance — the DDF committee meeting makes the final approval; once approved, the registration certificate is issued.
GRZAN note: registration in Cambodia involves 6 steps; the technical dossier follows 1 template (the 7 modules of the ASEAN CSDT); final approval rests with the DDF committee, whose meeting cycle is roughly 3 to 4 months.
2. Legal basis
| Legal instrument | Number / reference | Date | Provisions |
|---|---|---|---|
| ASEAN Medical Device Directive (AMDD) | signed by the 10 ASEAN member states | Article 22: entered into force 1 January 2015 | Article 4 and Annexes 2/3 (classification); Article 8 and Annex 4 (CSDT); Article 1(2) (registration obligation) |
| Prakas No. 1258 on Medical Device Registration Procedures | Prakas No. 1258 | 8 November 2012 | registration procedures and dossier requirements |
| Official CamPORS documentation | launched by the Ministry of Health, WHO-supported | 1 August 2019 | account opening process; registrable categories include medical devices |
| Amendment Law to the Law on Drug Management | Royal Decree No. NS/RPhM/1207/037 | adopted 8 November 2007 | Article 8 (new), paragraph 2 (registration number) |
3. Expert insights
- Cambodia’s process bottleneck is not the volume of documents but the “window”. Of the six steps, the least controllable is step 6 — the DDF committee meets roughly every 3 to 4 months to make final approvals; if the assessment is not completed before the current meeting, the application is carried over to the next round. This means every missed window costs 3 to 4 months. The marginal return on polishing documents is far lower than the marginal return on managing the schedule.
- “Hybrid submission” is the product of a paper era overlapping a digital one. CamPORS was designed for a fully paperless process, but for devices the authorities still require paper originals of the administrative documents and a USB copy of the technical dossier. This is not an option that can be simplified away — it is the currently accepted submission format at DDF; preparing purely online or purely on paper will lead to rejection.
- Payment falls “after assessment is complete and before committee review”, which makes it a useful information node. The appearance of the payment notice means DDF’s technical assessment has concluded and the application is about to enter committee scheduling. For project management, this is the only public signal that allows backward calibration of the schedule — applicants should count back from the date of the payment notice to the next committee window.
4. Practical recommendations
- Schedule the submission date backwards from the committee calendar. First confirm with the local entity the actual meeting months of the three most recent committee meetings, then derive the document freeze date from those; do not fix the document completion date first and then wait for meetings.
- Make “passing pre-review on the first attempt” the single quality objective. Because there is no inter-department appeal buffer, the cost of a rejected pre-review is not a few days but possibly an entire missed committee window. A full third-party dossier pre-review before submission is recommended.
- Set milestones and owners for each of the six steps. Classification is owned by regulatory affairs, the account by the local entity, dossier preparation jointly by regulatory and translation teams, submission by the local entity, payment with finance support, and schedule tracking by the project manager. The six steps span three organisations; without clearly assigned owners, waiting is inevitable.
5. Verification checklist
- □ Classification into A/B/C/D completed and documented in writing
- □ CamPORS account opened (originals verified by DDF)
- □ Paper administrative dossier and USB technical dossier both complete
- □ Hybrid submission completed: online entry + paper + USB
- □ DDF payment notice received and fee paid
- □ Committee meeting schedule tracker established and submission date back-planned
Regulatory information verified as of 29 October 2026.
In Southeast Asian markets, GRZAN’s core capabilities concentrate on three points. First, distinguishing the legislative progress of dedicated medical device laws across member states — Singapore, Malaysia, Thailand, Indonesia, the Philippines and Vietnam have each established written device regulatory frameworks, whereas Cambodia still has no dedicated Medical Device Law; the current rules are assembled from three layers: the registration-number legal basis provided by the 1996 Law on Drug Management and its 2007 amendment, the classification and procedures provided by Prakas No. 1258 of 2012, and the technical framework provided by the ASEAN Medical Device Directive. Compliance certainty is therefore markedly lower than in markets that have completed legislation. Second, local authorised representative services: GRZAN can act as the manufacturer’s statutory representative in Cambodia, undertaking registration submission, regulatory communication and post-market reporting obligations, and assisting with the practical requirements for a Cambodian registered pharmacist and a drug import-export enterprise licence. Third, quality system and testing support: helping establish a quality management system that meets ISO 13485 requirements and organising the technical dossier under the ASEAN Common Submission Dossier Template (CSDT).
Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us